TABLE I.
Patient characteristics by anti-hormonal treatment status
| Characteristic | Anti-hormonal treatment | ||
|---|---|---|---|
|
| |||
| Yes | No | Overall | |
| Patients (n) | 661 | 1560 | 2221 |
| Mean age (years) | 59.4±11.1 | 53.5±13.1 | 55.3±12.8 |
| Mean BMI (kg/m2) | 24.7±4.4 | 23.7±4.0 | 24.0±4.2 |
| Missing [n (%)] | 11 (1.6) | 47 (3.0) | 58 (2.6) |
| Tumour size [n (%)] | |||
| ≤20 mm | 301 (45.5) | 819 (52.5) | 1120 (50.4) |
| 21–50 mm | 225 (43.1) | 585 (37.5) | 870 (39.2) |
| >50 mm | 52 (7.8) | 104 (6.7) | 156 (7.0) |
| Missing | 23 (3.5) | 52 (3.3) | 75 (3.4) |
| Axillary nodes [n (%)] | |||
| 0 | 248 (37.5) | 870 (55.8) | 1118 (50.3) |
| 1–3 | 225 (34.0) | 347 (22.2) | 572 (25.8) |
| >3 | 128 (19.4) | 219 (14.0) | 347 (15.6) |
| Unknown | 60 (9.1) | 124 (8.0) | 184 (8.3) |
| Estrogen receptor [n (%)] | |||
| 0–3 fmol/mg | 40 (6.1) | 343 (22.0) | 383 (17.2) |
| 4–9 fmol/mg | 46 (7.0) | 220 (14.1) | 266 (12.0) |
| 10–19 fmol/mg | 100 (15.1) | 196 (12.6) | 296 (13.3) |
| 20–49 fmol/mg | 171 (25.9) | 267 (17.1) | 438 (19.7) |
| ≥50 fmol/mg | 304 (46.0) | 534 (34.2) | 838 (37.7) |
| Progesterone receptor [n (%)] | |||
| 0–9 fmol/mg | 205 (31.0) | 627 (40.2) | 832 (37.5) |
| ≥10 fmol/mg | 421 (63.7) | 804 (51.5) | 1225 (55.2) |
| Unknown | 35 (5.3) | 129 (8.27) | 164 (7.4) |
| Surgery type [n (%)] | |||
| Total mastectomy | 282 (42.7) | 788 (50.5) | 1070 (48.2) |
| Lumpectomy and RT | 294 (44.5) | 615 (39.4) | 909 (41.0) |
| Other | 85 (12.9) | 157 (10.1) | 242 (10.9) |
| Chemotherapy [n (%)] | |||
| Yes | 100 (15.1) | 450 (28.9) | 550 (24.8) |
| No | 561 (84.9) | 1110 (71.2) | 1671 (75.2) |
| Death | |||
| Breast cancer | 216 (32.7) | 556 (35.6) | 772 (34.8) |
| Overall | 336 (50.8) | 830 (53.2) | 1166 (52.5) |
BMI = body mass index; RT = radiotherapy.